{"id":3827,"date":"2025-03-31T18:11:50","date_gmt":"2025-03-31T18:11:50","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/chlorambucil-txt\/"},"modified":"2025-03-31T18:11:50","modified_gmt":"2025-03-31T18:11:50","slug":"chlorambucil-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/chlorambucil-txt\/","title":{"rendered":"Chlorambucil.txt"},"content":{"rendered":"

Chlorambucil<\/h1>\n

CLINICAL USE <\/H3>
\nAlkylating agent:<\/p>\n
  • Hodgkin\u2019s disease\n
  • Non-Hodgkin\u2019s lymphoma (NHL)\n
  • Chronic lymphocytic leukaemia (CLL)\n
  • Waldenstr\u00f6m\u2019s macroglobulinaemia (WM)\n
  • Ovarian carcinoma (OC)\n
  • Advanced breast cancer (ABC)

    DOSE IN NORMAL RENAL FUNCTION <\/H3>\n
  • Hodgkin\u2019s disease: 200 mcg\/kg\/day (4\u20138 wks)\n
  • NHL: 100\u2013200 mcg\/kg\/day (4\u20138 wks) then reduce dose or give intermittently\n
  • CLL: initially 150 mcg\/kg\/day, then 4 weeks after 1st course ended 100 mcg\/kg\/day\n
  • WM = initially 6\u201312 mg daily, then reduce to 2\u20138 mg daily\n
  • OC = 200 mcg\/kg\/day\n
  • ABC = 200 mcg\/kg\/day for 6 wks (or 14\u201320 mg\/day)

    PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :304.2<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :99<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : <1<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :0.86<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :1.5\/\u2013

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function. See \u2018Other Information\u2019
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function. See \u2018Other Information\u2019
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function. See \u2018Other Information\u2019

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in normal renal function
  • CAV\/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Ciclosporin: ciclosporin concentration possibly reduced\n
  • Patients who receive phenylbutazone may require reduced doses of chlorambucil

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>\n
  • Chlorambucil is extensively metabolised in the liver via the hepatic microsomal enzyme oxidation system, principally to phenylacetic acid mustard, which is pharmacologically active\n
  • Chlorambucil is excreted in the urine, almost exclusively as metabolites\n
  • Monitor patients with renal impairment closely as they are at increased risk of myelosuppression associated with azotaemia\n
  • Oral absorption slowed and decreased by 10 to 20 % if ingested with food.
    \n","protected":false},"excerpt":{"rendered":"

    Chlorambucil CLINICAL USE Alkylating agent: Hodgkin\u2019s disease Non-Hodgkin\u2019s lymphoma (NHL)<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3827","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3827","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3827"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3827\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3827"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3827"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3827"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}